A patient with ER-positive, HER2-negative, node-negative breast cancer has a 21-gene recurrence score (Oncotype DX) of 16. She is 55 years old and postmenopausal. The TAILORX trial result most applicable to her management is:

• A Chemotherapy plus endocrine therapy provides significant benefit over endocrine therapy alone
• B Endocrine therapy alone is non-inferior to chemoendocrine therapy ✓
• C Chemotherapy should be added because she is over 50 years
• D Score of 16 falls in the high-risk category requiring chemotherapy

Explanation

TAILORX showed that for postmenopausal women with a recurrence score of 0–25, endocrine therapy alone was non-inferior to chemoendocrine therapy. A score of 16 falls in the intermediate range (11–25) where chemotherapy was not beneficial in postmenopausal women; it may benefit younger premenopausal women with scores 16–25. Score > 25 is high-risk.

Reference: Bailey & Love's Short Practice of Surgery, 27th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.